CDK4 and melanoma: This study suggested that combined MEK inhibitor with CDK4/6 inhibitor may be clinically more active in NRASmut melanoma patients with concurrent genetic alterations (such as CDKN2A, CDK4, or CCND1) in G1 cell‐cycle checkpoint than MEK inhibition alone.